Actinium Pharmaceuticals (OTC:ATNM) is a cancer-focused biotech that is fundamentally misunderstood due to a perfect storm of "valuation limiting" factors that provide a classic low risk/high reward investment opportunity. The current valuation does not accurately reflect the significant potential licensing opportunities or attractiveness to a larger acquirer given the current M&A environment.
ATNM focuses on the development of cancer drugs based on its proprietary Alpha Particle Immunotherapy platform, which is potentially applicable to a wide variety of cancers. This is a highly potent and selective form of targeted radiotherapy, in which powerful alpha emitting radioisotopes (Actinium 225* or Bismuth 213) are carried by monoclonal antibodies (mAbs) directly to cancer cells.
ATNM has two clinical stage drugs:...